Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment

卡波扎尼布 肝细胞癌 医学 肿瘤科 免疫检查点 内科学 免疫疗法 癌症 肾细胞癌
作者
Stephen L. Chan,Baek‐Yeol Ryoo,Frankie Mo,Landon L. Chan,Jaekyung Cheon,Leung Li,Kwan Hung Wong,Nicole Yim,Hyeyeong Kim,Changhoon Yoo
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:81 (2): 258-264 被引量:17
标识
DOI:10.1016/j.jhep.2024.03.033
摘要

Abstract

Background and Aims

There has been a lack of prospective data on treatment after immune checkpoint inhibitor (ICI) in hepatocellular carcinoma (HCC). We conducted a phase II multicentred study on cabozantinib in HCC after ICI treatment.

Methods

This is an investigator-initiated single-arm clinical trial involving academic centres in Hong Kong and Korea. Key eligibility criteria include diagnosis of HCC; refractoriness to prior ICI-based treatment; Child-Pugh A liver function. Maximally two prior lines of therapy were allowed. All patients were commenced cabozantinib at 60mg/day. The primary endpoint was progression-free survival (PFS).

Results

Total 47 patients were recruited from Oct 2020 to May 2022. The median follow-up was 11.2 months. In the study, 27 and 20 patients received one and two prior therapies. The median PFS was 4.1 months (95%CI:3.3-5.3). The median OS was 9.9 months (95%CI:7.3-14.4), and the 1-year OS rate was 45.3%. Partial response and stable disease occurred in 3 (6.4%) and 36 (76.6%) of patients. When used as a second-line treatment (n=20), cabozantinib was associated with a median PFS and OS of 4.3 (95%CI:3.3-6.7) and 14.3 months (95%CI:8.9-NR). The corresponding median PFS and OS was 4.3 (95%CI:3.3-11.0) and 14.3 months (95%CI:9.0-NR) for those receiving ICI-based regimen with proven benefits (n=17). Commonest grade 3-4 TRAE was thrombocytopenia (6.4%). The median dose of cabozantinib was 40mg/day. The number of prior therapy was an independent prognosticator (one vs. two; HR=0.37; p=0.03).

Conclusions

Cabozantinib demonstrates efficacy in patients with prior ICI. The survival data of second-line cabozantinib following the first-line ICI regimen provide reference for clinical trial testing post-ICI therapy. The number of prior line of treatment may be considered a stratification factor in randomized study.

Impact and Implications

There is a lack of prospective data on systemic therapy following prior immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC). The current phase II clinical trial reported the efficacy and safety data of cabozantinib in patients with prior ICI-based treatment. Exploratory analyses showed that the performance of cabozantinib differed significantly when used as second or third-line treatment. The above data could be used a reference for clinical practice and design of future clinical trials on subsequent treatment following ICIs.

Trial registration

ClinicalTrials.gov Identifier: NCT04588051.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
liuxian完成签到 ,获得积分10
2秒前
桐桐应助cruise采纳,获得10
2秒前
Dyson完成签到,获得积分10
2秒前
LYY完成签到,获得积分10
2秒前
柯一一应助称心的菲鹰采纳,获得10
3秒前
lixiaolu发布了新的文献求助10
3秒前
二艺发布了新的文献求助10
5秒前
qweasdzxcqwe发布了新的文献求助10
6秒前
可可发布了新的文献求助10
6秒前
搜集达人应助CC悟了采纳,获得10
7秒前
豆子应助陈诺采纳,获得20
7秒前
搜集达人应助白小白采纳,获得10
7秒前
7秒前
7秒前
8秒前
8秒前
11秒前
量子星尘发布了新的文献求助10
12秒前
12秒前
睡睡发布了新的文献求助10
12秒前
13秒前
13秒前
A2QD发布了新的文献求助10
13秒前
16秒前
16秒前
16秒前
Sober发布了新的文献求助10
18秒前
DarknessDuck完成签到,获得积分10
19秒前
ZCL完成签到 ,获得积分10
19秒前
祝您发财发布了新的文献求助10
20秒前
21秒前
Cq发布了新的文献求助10
21秒前
Ushur完成签到,获得积分10
21秒前
21秒前
bkagyin应助qweasdzxcqwe采纳,获得10
24秒前
24秒前
25秒前
搜集达人应助咪咪采纳,获得30
26秒前
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975693
求助须知:如何正确求助?哪些是违规求助? 3520019
关于积分的说明 11200635
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798255
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390